^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    lenalidomide

    i
    Other names: IMiD3, CDC 5013, CC-5013, CDC-501, CDC-5013, IMiD-1, IMiD-3, ENMD-0997, CC 5013, CDC 5013, ENMD 0997
    Company:
    Generic mfg.
    Drug class:
    TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor
    Related drugs:
    2d
    NANT 2013-01: Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells (clinicaltrials.gov)
    P1, N=13, Active, not recruiting, New Approaches to Neuroblastoma Therapy Consortium | Trial completion date: Sep 2025 --> Dec 2026 | Trial primary completion date: Sep 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    lenalidomide • Unituxin (dinutuximab)
    4d
    ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=47, Active, not recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Mar 2026 --> Mar 2028 | Trial completion date: Mar 2026 --> Mar 2028
    Trial completion date • Trial primary completion date
    |
    Rituxan (rituximab) • lenalidomide • Truxima (rituximab-abbs) • evorpacept (ALX148)
    7d
    A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma (clinicaltrials.gov)
    P3, N=0, Withdrawn, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | N=300 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Breyanzi (lisocabtagene maraleucel) • bendamustine • fludarabine IV
    8d
    Early intervention for high-risk smoldering multiple myeloma (SMM). (PubMed, Cochrane Database Syst Rev)
    Early intervention with daratumumab may reduce the risk of disease progression and mortality in people with high-risk SMM. The evidence on the risk of adverse events with daratumumab is very uncertain. For immunomodulatory agents, the available evidence is of very low certainty, partly due to conflicting results, so we are unable to draw conclusions about their effects. There is insufficient evidence to support the use of older agents like alkylating agents or cytokine inhibitors. The decision to initiate early treatment in high-risk SMM requires a careful, individualized risk-benefit assessment and shared decision-making.
    Clinical • Review • Journal
    |
    CD40LG (CD40 ligand)
    |
    lenalidomide • Darzalex (daratumumab) • prednisone • thalidomide • melphalan • Sylvant (siltuximab)
    8d
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P1, N=258, Not yet recruiting, Shanghai Henlius Biotech
    New P1 trial
    |
    lenalidomide • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    8d
    IFm2022-01: Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P2, N=103, Active, not recruiting, Nantes University Hospital | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2026 --> Apr 2028
    Enrollment closed • Trial primary completion date • Minimal residual disease
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • dexamethasone • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    9d
    A Study of Daratumumab (clinicaltrials.gov)
    P3, N=500, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Jan 2026 --> Jan 2029
    Trial primary completion date
    |
    lenalidomide • Darzalex (daratumumab) • carfilzomib • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • dexamethasone injection
    9d
    EMAT: Elimination of Minimal Residual Disease After Transplant (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, Medical College of Wisconsin | Recruiting --> Active, not recruiting
    Enrollment closed • Minimal residual disease
    |
    clonoSEQ
    |
    lenalidomide • Sarclisa (isatuximab-irfc) • dexamethasone injection
    12d
    A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, Massachusetts General Hospital | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial primary completion date
    |
    lenalidomide • Hiltonol (poly-ICLC) • PVX-410 • citarinostat (ACY-241)
    12d
    IDH2 Clonal Hematopoiesis and IKAROS Loss Cooperate in a B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma. (PubMed, Blood)
    Subsequent genetic or epigenetic alterations render leukemogenesis independent of ongoing lenalidomide exposure. Altogether, these data define IDH2mt B-ALL as a distinct molecular subtype that is markedly overrepresented after lenalidomide treatment and highlight clonal hematopoiesis as a key contributing factor in the development of LenB-ALL.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • IKZF1 (IKAROS Family Zinc Finger 1)
    |
    TP53 mutation • IDH2 mutation
    |
    lenalidomide
    13d
    Combining lenalidomide with IL-2 family of cytokines enhances activating receptor and perforin/granzyme expression in NK cells. (PubMed, PLoS One)
    These data provide a rationale for the combination of lenalidomide with IL-2 family of cytokines to enhance the effectiveness of NK cells.
    Journal
    |
    IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • IL15 (Interleukin 15) • PRF1 (Perforin 1)
    |
    lenalidomide